MINNEAPOLIS--(BUSINESS WIRE)--Aradigm Corporation (OTC BB: ARDM) today presented Phase 1 trial results demonstrating that inhaling water solution of nicotine using Aradigm’s AERx Essence® palm-size inhaler results in very rapid absorption of nicotine into the blood stream and appears to be associated with acute reduction of craving for cigarettes. Aradigm believes these results provide the foundation for further research with the AERx Essence device as a means toward smoking cessation. These results were made public via a poster presentation by Tunde Otulana, M.D., Aradigm’s Chief Medical Officer, at the National Conference on Tobacco or Health underway at the Minneapolis Convention Center.
